Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Sponsor: Shire
Listed as NCT01328756, this PHASE4 trial focuses on Attention Deficit Hyperactivity Disorder (ADHD) and remains completed. Sponsored by Shire, it has been updated 9 times since 2011, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badajoz, Spain , Bamberg, Germany , Barcelona, Spain , Berlin, Germany , Bucharest, Romania , Budapest, Hungary , Bydgoszcz, Poland , Cagliari, Italy , Dundee, United Kingdom , Esplugues de Llobregat, Spain and 25 more locations